他汀类药物与新发糖尿病的关系,已知的报道结果并不一致。WOSCOPS研究表明,普伐他汀降低糖尿病的发生率。然而,JUPITER试验首次报告他汀类药物增加糖尿病发生率。他汀类药物使新发糖尿病的风险增加9%,每255例患者接受他汀类药物治疗4年,将有1例新发糖尿病[1]。他汀类药物的剂量和种类可能会影响新发糖尿病的风险,普伐他汀40 mg/d风险最低,为7%,瑞舒伐他汀20 mg/d风险最 The relationship between statins and new-onset diabetes is not consistent with known reports. WOSCOPS study shows that pravastatin reduces the incidence of diabetes. However, the JUPITER trial reported for the first time that statins increased the incidence of diabetes. Statins increase the risk of new-onset diabetes by 9% and every 255 patients receive statin therapy for 4 years, there will be 1 case of new-onset diabetes [1]. The dose and type of statin may have an impact on the risk of new-onset diabetes with the lowest risk of pravastatin 40 mg / day being 7% and the risk of rosuvastatin 20 mg / day being the lowest